Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$21.0 - $29.1 $35,826 - $49,644
-1,706 Reduced 58.46%
1,212 $26,000
Q4 2023

Feb 14, 2024

SELL
$19.72 - $28.68 $45,789 - $66,594
-2,322 Reduced 44.31%
2,918 $80,000
Q2 2023

Aug 14, 2023

SELL
$20.96 - $26.99 $56,654 - $72,953
-2,703 Reduced 34.03%
5,240 $133,000
Q1 2023

May 12, 2023

SELL
$20.58 - $27.89 $80,961 - $109,719
-3,934 Reduced 33.12%
7,943 $177,000
Q4 2022

Feb 13, 2023

SELL
$15.31 - $29.94 $88,170 - $172,424
-5,759 Reduced 32.65%
11,877 $281,000
Q3 2022

Nov 08, 2022

SELL
$16.58 - $27.9 $52,674 - $88,638
-3,177 Reduced 15.26%
17,636 $293,000
Q2 2022

Aug 08, 2022

SELL
$15.45 - $29.52 $60,409 - $115,423
-3,910 Reduced 15.82%
20,813 $414,000
Q1 2022

May 17, 2022

SELL
$21.94 - $42.51 $148,709 - $288,132
-6,778 Reduced 21.52%
24,723 $682,000
Q4 2021

Feb 15, 2022

SELL
$36.09 - $53.79 $225,779 - $336,510
-6,256 Reduced 16.57%
31,501 $1.3 Million
Q3 2021

Nov 12, 2021

SELL
$35.62 - $52.97 $200,611 - $298,327
-5,632 Reduced 12.98%
37,757 $1.75 Million
Q2 2021

Jul 30, 2021

SELL
$32.94 - $56.62 $113,247 - $194,659
-3,438 Reduced 7.34%
43,389 $1.74 Million
Q1 2021

May 07, 2021

BUY
$44.47 - $81.38 $375,326 - $686,847
8,440 Added 21.99%
46,827 $2.52 Million
Q4 2020

Feb 12, 2021

BUY
$32.49 - $61.88 $413,857 - $788,227
12,738 Added 49.66%
38,387 $1.88 Million
Q3 2020

Nov 16, 2020

BUY
$26.73 - $35.67 $368,660 - $491,960
13,792 Added 116.32%
25,649 $833,000
Q2 2020

Aug 12, 2020

BUY
$19.49 - $28.11 $95,247 - $137,373
4,887 Added 70.11%
11,857 $307,000
Q1 2020

May 15, 2020

SELL
$16.13 - $30.17 $1,467 - $2,745
-91 Reduced 1.29%
6,970 $169,000
Q4 2019

Feb 14, 2020

BUY
$20.78 - $29.99 $13,403 - $19,343
645 Added 10.05%
7,061 $197,000
Q3 2019

Nov 14, 2019

BUY
$23.87 - $30.93 $72,373 - $93,779
3,032 Added 89.6%
6,416 $154,000
Q2 2019

Aug 14, 2019

BUY
$22.1 - $28.56 $74,786 - $96,647
3,384 New
3,384 $96,000

Others Institutions Holding VCYT

About VERACYTE, INC.


  • Ticker VCYT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 71,575,904
  • Market Cap $3.23B
  • Description
  • Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...
More about VCYT
Track This Portfolio

Track Advisors Asset Management, Inc. Portfolio

Follow Advisors Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisors Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisors Asset Management, Inc. with notifications on news.